CRIS Current Research Information System

GRAMENZI, ANNAGIULIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.672
AS - Asia 6.010
EU - Europa 4.412
AF - Africa 372
SA - Sud America 320
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 4
Totale 17.796
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.616
VN - Vietnam 2.127
SG - Singapore 1.473
CN - Cina 1.268
GB - Regno Unito 1.018
IT - Italia 697
SE - Svezia 632
DE - Germania 539
HK - Hong Kong 368
FR - Francia 285
IN - India 267
RU - Federazione Russa 217
BR - Brasile 213
IE - Irlanda 184
UA - Ucraina 183
NL - Olanda 153
CH - Svizzera 127
TG - Togo 114
KR - Corea 110
ZA - Sudafrica 92
JP - Giappone 83
CI - Costa d'Avorio 78
FI - Finlandia 76
EE - Estonia 75
JO - Giordania 73
BG - Bulgaria 53
BE - Belgio 40
TH - Thailandia 37
BD - Bangladesh 33
SC - Seychelles 33
AR - Argentina 32
CA - Canada 28
IR - Iran 24
PH - Filippine 23
EC - Ecuador 22
ID - Indonesia 22
GR - Grecia 21
NG - Nigeria 19
HR - Croazia 18
AT - Austria 16
CL - Cile 16
TW - Taiwan 16
ES - Italia 15
PL - Polonia 14
UZ - Uzbekistan 14
PK - Pakistan 13
IQ - Iraq 12
VE - Venezuela 12
CO - Colombia 11
MX - Messico 11
TR - Turchia 11
ET - Etiopia 10
HU - Ungheria 8
LB - Libano 8
MY - Malesia 8
EG - Egitto 6
MA - Marocco 6
PT - Portogallo 6
AU - Australia 5
CR - Costa Rica 5
CZ - Repubblica Ceca 5
LT - Lituania 5
PY - Paraguay 5
RO - Romania 5
SA - Arabia Saudita 5
AE - Emirati Arabi Uniti 4
DK - Danimarca 4
KZ - Kazakistan 4
TN - Tunisia 4
UY - Uruguay 4
MK - Macedonia 3
PE - Perù 3
SK - Slovacchia (Repubblica Slovacca) 3
SV - El Salvador 3
BO - Bolivia 2
CG - Congo 2
DM - Dominica 2
LU - Lussemburgo 2
MU - Mauritius 2
RS - Serbia 2
TT - Trinidad e Tobago 2
XK - ???statistics.table.value.countryCode.XK??? 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AO - Angola 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CV - Capo Verde 1
CY - Cipro 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EU - Europa 1
GE - Georgia 1
GH - Ghana 1
GL - Groenlandia 1
HN - Honduras 1
IS - Islanda 1
JM - Giamaica 1
KG - Kirghizistan 1
LV - Lettonia 1
MT - Malta 1
Totale 17.787
Salva come PNG Salva come JPEG
Città #
Singapore 1.011
Southend 879
Fairfield 750
Ashburn 682
Chandler 532
Ho Chi Minh City 495
Hanoi 402
Hong Kong 334
Woodbridge 334
Houston 328
Dong Ket 326
San Jose 308
Seattle 282
Wilmington 267
Cambridge 242
Ann Arbor 229
Santa Clara 229
Princeton 213
Bologna 193
Dublin 183
Hefei 182
Beijing 161
Boardman 140
Bern 116
Lomé 114
Jacksonville 110
Lauterbourg 106
Seoul 88
Westminster 88
Da Nang 83
Dallas 83
Los Angeles 81
Abidjan 78
Padova 77
Nanjing 75
Amman 72
Milan 69
Council Bluffs 68
New York 68
Tokyo 68
Haiphong 62
Berlin 60
Redmond 57
Helsinki 56
Shenyang 52
Jinan 50
Sofia 50
Buffalo 46
Munich 46
Saint Petersburg 45
Florence 42
San Diego 42
Brussels 39
Changsha 39
Turin 36
Frankfurt am Main 34
Hải Dương 33
Guangzhou 30
Redondo Beach 29
São Paulo 29
Bremen 27
Tianjin 27
Medford 26
Nanchang 24
Shanghai 24
Dearborn 23
Des Moines 23
Biên Hòa 22
Can Tho 22
Falkenstein 22
Hebei 22
Phoenix 21
London 20
Paris 20
Thái Nguyên 20
Zhengzhou 20
Hangzhou 19
Jiaxing 19
Mülheim 19
Rome 19
Wuhan 19
Abeokuta 18
Amsterdam 18
Bengaluru 18
Norwalk 18
Vũng Tàu 18
Bến Tre 17
Ha Long 17
Chicago 16
Falls Church 16
Mahé 16
Turku 16
Orem 15
The Dalles 15
Bangkok 14
Bắc Ninh 14
Nha Trang 13
Nuremberg 13
Quận Bình Thạnh 13
Redwood City 13
Totale 11.779
Salva come PNG Salva come JPEG
Nome #
G-CSF administration is not related to PEG-IFN alfa-213 treatment duration nor response in liver transplanted patients with HCV recurrence 510
Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation 303
Monofocal hepatocellular carcinoma: How much does size matter? 283
Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: A pilot case-control study 278
Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis. 260
G-CSF administration is not related to Peg-IFN alfa-2b treatment duration nor response in liver transplanted patients with HCV recurrence. 243
A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma 239
Radiomics of cholangiocarcinoma on pretreatment CT can identify patients who would best respond to radioembolisation 239
Cytokine profile of peripheral blood mononuclear cells from patients with different outcomes of hepatitis C virus infection. 236
Yttrium-90 radioembolization for unresectable/recurrent intrahepatic cholangiocarcinoma: a survival, efficacy and safety study 234
Computed Tomography-Colonography With Intravenous Contrast Medium and Urographic Phase for the Evaluation of Pelvic Deep Infiltrating Endometriosis of Intestinal and Urinary Tract 234
Pattern of macrovascular invasion in hepatocellular carcinoma 233
Recalibrating survival prediction among patients receiving trans‐arterial chemoembolization for hepatocellular carcinoma 230
A new prognostic model to predict drop-out from the waiting list in cirrhotic candidates for liver transplantation wirh MELD score <18. 225
Acquired intestinal lymphangiectasia successfully treated with a low fat and MCT-enriched diet in a patient with liver transplantation. 224
Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs 218
Yttrium-90 microsphere radioembolization in unresectable intrahepatic cholangiocarcinoma 218
BCLC stage B hepatocellular carcinoma and transcatheter arterial chemoembolization: a 20-year survey by the Italian Liver Cancer group. 216
Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma. 216
Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon 215
Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatments and outcome. 209
Application of the Intermediate-Stage Subclassification to Patients with Untreated Hepatocellular Carcinoma 208
Correlation between LDH levels and response to sorafenib in HCC patients: an analysis of the ITA.LI.CA. database 205
Long term follow-up and outcome of liver transplantation for alcoholic liver disease: a single center case-control study 204
Thymosin-alpha 1 plus interferon-alpha for naive patients with chronic hepatitis C: results of a randomized controlled pilot trial 203
Hepatitis C Virus-related chronic liver disease in elderly patients: an Italian cross-sectional study. 203
The changing scenario of hepatocellular carcinoma in Italy: an update 200
Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: a 20 year multicentre experience. 199
Vitamins in the treatment of chronic viral hepatitis. 198
Influence of clinically significant portal hypertension on survival after hepatic resection for hepatocellular carcinoma in cirrhotic patients 197
Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma 197
Serum hepatitis B surface antigen monitoring in long-term Lamivudine-treated hepatitis B virus patients 194
Metabolic disorders across hepatocellular carcinoma in Italy 193
Pegylated interferon plus ribavirin for recurrent Hepatitis C infection after liver transplantation in naive and non-responder patients on a stable immunosuppressive regimen. 192
Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment 189
Alcoholic liver disease: pathophisiological aspects and risk factors. A review. 188
Impact of Sarcopenia on the Survival of Patients with Hepatocellular Carcinoma Treated with Sorafenib 186
Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma 186
Impact of etiology of cirrhosis on the survival of patients diagnosed with hepatocellular carcinoma during surveillance. 184
A new approach to the use of α-fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis. 182
Liver transplantation for patients with alcoholic liver disease: an open question 180
In vitro effect of thymosin-alpha1 and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with eAg-negative chronic hepatitis B. 178
Survival and Tolerability of Transarterial Chemoembolization in Greater Versus less than 70 Years of Age Patients with Unresectable Hepatocellular Carcinoma: A Propensity Score Analysis 178
Surveillance for hepatocellular carcinoma in elderly italian patients with cirrhosis. Effects on cancer staging and patients survival. 175
Hepatitis B virus and immune response. 172
High incidence of allograft dysfunction in liver transplant patients treated with PEG-Interferon alfa-2b and Ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis? 172
Hepatocellular carcinoma appearance in patients with hepatitis C virus-related chronic liver disease 90 and 70 months after sustained virological response to interferon and ribavirin 169
High risk of hepatocellular carcinoma in anti-HBe positive liver cirrhosis patients developing Lamivudine resistance. 168
Outcome of hepatocellular carcinoma in human immunodeficiency virus-infected patients. 168
Development and validation of a scoring system that includes corrected QT interval for risk analysis of patients with cirrhosis and gastrointestinal bleeding 168
In vitro effect of indomethacin and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with chronic hepatitis C 167
Metronomic capecitabine in advanced hepatocellular carcinoma patients:a phase II study. 166
Stem cell mobilization and collection in patients with liver cirrhosis. 165
Biomarkers for the early diagnosis of bacterial infection and the surveillance of hepatocellular carcinoma in cirrhosis 165
Two years Mycophenolate Mofetil plus low dose calcineurin inhibitor for renal dysfunction after liver transplantation. 165
null 164
Immunological modifications during treatment with thymosin alpha 1 plus antiviral therapy in chronic hepatitis C. 162
Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. 162
Factors that affect efficacy of ultrasound surveillance for early stage hepatocellular carcinoma in patients with cirrhosis. 158
Mobilization of bone marrow-derived hematopoietic and endothelial stem cells after orthotopic liver transplantation and liver resection. 156
Years of life that could be saved from prevention of hepatocellular carcinoma. 155
Probiotics History. 152
Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer population. 150
Hepatitis C virus (HCV) infection in elderly patients: A multicenter Italian cross-sectional study 149
Authors’ reply: Comment to “Liver transplantation for patients with alcoholic liver disease: An open question” 149
Redefinition of diagnostic role of inferior vena cava ultrasonography in the identification of acute heart failure. 147
Reply to “Re: Survival and Tolerability of Transarterial Chemoembolization in Greater Versus less than 70 Years of Age Patients with Unresectable Hepatocellular Carcinoma—A Propensity Analysis” 147
Ketoprofen, peginterferon-alpha2a and ribavirin for genotype 1 chronic hepatitis C: a phase II study. 146
Six score systems to evaluate candidates with advanced cirrhosis for orthotopic liver transplant: which is the winner? 145
A randomized trial of induction doses of interferon alone or in combination with ribavirin or ribavirin plus amantadine for treatment of non-responder patients with chronic hepatitic C. 144
The evolutionary scenario of hepatocellular carcinoma in Italy: an update. 144
Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study. 140
Transcatheter arterial chemoembolization therapy for patients with hepatocellular carcinoma: a case controlled study 140
Reply to: "Sorafenib or (90) Y loaded resin microsphere radioembolization for locally-advanced hepatocellular carcinoma, what should we trust?" 138
Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study 136
Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis 134
GRANULOCYTE COLONY STIMULATING FACTOR (G-CSF) ADMINISTRATION IN CIRRHOTIC PATIENTS: A PHASE II STUDY EVALUATING TOLERABILITY PROFILE AND MOBILIZATION OF HAEMATOPOIETIC STEM CELLS (HSCS). 132
Hepatocellular carcinoma in patients with cryptogenic cirrhosis 131
Surveillance for early diagnosis of hepatocellular carcinoma: is it effective in intermediate/advanced cirrhosis? 129
TRANS-ARTERIAL RADIOEMBOLIZATION FOR INTERMEDIATE-ADVANCED HEPATOCELLULAR CARCINOMA: A BUDGET IMPACT ANALYSIS 129
Vitamin E as treatment for chronic viral hepatitis: is it time to perform large clinical trials? 125
La radioembolizzazione nel trattamento del colangiocarcinoma intraepatico inoperabile: efficacia, sopravvivenza e sicurezza 125
OUTCOME OF LIVER TRANSPLANT FOR ALCOHOLIC LIVER DISEASE. 124
PEGYLATED INTERFERON PLUS RIBAVIRIN FOR THE TREATMENT OF RECURRENT HCV INFECTION AFTER LIVER TRANSPLANTATION 117
null 117
Hepatic artery stenosis in liver transplanted patients treated with pegylated Interferon alpha-2b and Ribavirin 116
Capitolo 14 "Epatiti Virali Croniche", Volume IX "Malattie del Fegato, delle Vie Biliari e del Pancreas", Trattato di Medicina Interna, fondato da Paolo Larizza 111
Hepatitis C in the elderly: a multicenter cross-sectional study by the Italian Association for the Study of the Liver. 110
Surveillance for hepatocellular carcinoma with a 3-months interval in "extremely high-risk" patients does not further improve survival 106
Radioembolizzazione con 90Y versus sorafenib nei pazienti cirrotici con carcinoma epatocellulare (HCC): studio monocentrico con analisi di propensity 105
Post-transplantation lymphoproliferative disorders in liver transplanted patients: a report of four cases 104
Senility 102
Role of CT colonography (CTC) in a regional colorectal cancer (CRC) screening programme: preliminary results. 100
OUTCOME OF LIVER TRANSPLANT FOR ALCOHOLIC LIVER DISEASE 97
Fegato e infezioni sistemiche. 96
SPONTANEOUS MOBILIZATIONOF BONE MARROW-DERIVED HEMATOPOIETIC AND ENDOTHELAIL PROGENITOR CELLS AFTER ORTHOTOPIC LIVER TRANSPALNTATION (OLT). 96
Surveillance for early diagnosis of hepatocellular carcinoma: is it effective in intermediate/advanced cirrhosis? 91
Sorafenib versus Y90 radioembolization in cirrhotic patients with hepatocellular carcinoma (HCC): cohort and nested control-case study with propensity analysis 87
Yttrium90 radioembolization versus sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis 85
null 83
Totale 17.263
Salva come PNG Salva come JPEG
Categoria #
all - tutte 47.129
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 47.129
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021674 0 0 0 0 0 0 0 0 0 73 81 520
2021/20222.147 157 86 121 202 170 121 56 134 63 166 550 321
2022/20232.379 231 364 112 314 120 189 87 119 398 80 189 176
2023/2024628 51 95 40 56 59 150 17 45 29 31 23 32
2024/20252.330 89 362 193 189 350 142 178 59 16 167 127 458
2025/20265.589 709 431 504 336 550 337 965 219 1.163 375 0 0
Totale 18.047